The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)

Shanghai Jiao Tong University

Status: Enrolling

Conditions: Advanced Colorectal Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06601075

RuijinH 2024-80

Details and patient eligibility

About

This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)

Full description

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 18F-FDG and 68Ga-FAPI PET/CT at baseline and after 3 months of conversion therapy. The imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases.
2. Patients voluntarily enrolled in this study by signing an informed consent form
3. Age ≥ 18 years
4. Expected life expectancy ≥ 3 months
5. Adequate organ and bone marrow function
6. Willingness to adhere to the study protocol and follow-up programme

Exclusion criteria

1. Pregnant or breastfeeding women.
2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis

Trial design

30 participants in 1 patient group

Patients diagnosis of advanced colorectal cancer

Description:

Patients diagnosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)